<div id="readability-page-1"><div><p><span>Gruber James R Chief Financial Officer of Eton Pharmaceuticals Inc [ETON] filed a Form 4 on December 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/12/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>4,542</span></td></tr><tr><td><span>Price</span></td><td><span>$16.99</span></td></tr><tr><td><span>Value</span></td><td><span>$77,169</span></td></tr></tbody></table></div><p><span>Ending Holdings: 215,713 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ETON

<p>Eton Pharmaceuticals CFO, Gruber James R, surrendered 4,542 shares back to the company to cover option exercise costs and tax liabilities. The transaction was filed with the SEC on December 12, 2025, at a price of $16.99 per share, totaling $77,169. Gruber's ending holdings are 215,713 shares directly.</p>

CFO Gruber Surrenders 4,542 Of Eton Pharmaceuticals Inc [ETON]